Drug Profile
TRI 50B
Alternative Names: TRI 50; TRI B50Latest Information Update: 22 Dec 2003
Price :
$50
*
At a glance
- Originator Thrombosis Research Institute
- Developer Thrombosis Research Institute; Trigen Ltd
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 22 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics and Thrombosis pharmacodynamics sections
- 18 Nov 2003 Discontinued - Clinical-Phase-Unknown for Thrombosis in Poland (IV)
- 18 Nov 2003 Discontinued - Phase-I for Thrombosis in United Kingdom (PO)